Baron & Budd Attorney and Shareholder Burton LeBlanc to Speak on Opioid Epidemic at American Association for Justice
BATON ROUGE, La. – November 17, 2017 – The national law firm of Baron & Budd is pleased to...READ MORE
Sometimes legal action seems to lull on and on.
Other times, it’s like there’s a tremendous landslide.
Here’s what you need to know about this very big day — and what this all means — for the victims of Levaquin and Avelox:
Two FDA advisory committees voted overwhelmingly in favor of a label change regarding the use of FLQs for three routine infections: Sinusitis, bronchitis and UTI. In voting in favor of the label change, the committee members voiced their deep concerns with the overuse of this powerful class of antibiotics.
To add more fire to the flames, many of the committee members recommended that the FDA withdraw its approval of this class of drugs for sinusitis. Many also urged the FDA to investigate what the FDA has called “Fluoroquinolone-Associated Disability”, a permanently disabling condition that can cause damage to different parts of your body.
This is groundbreaking news for the countless patients who were seriously hurt by Levaquin, Avelox and other potentially dangerous fluoroquinolone antibiotics.
Fluoroquinolones are a very strong type of antibiotic that may carry serious associated risks like peripheral neuropathy. When these serious risks were undermined by marketing ploys that targeted Levaquin and Avelox as a strong choice for first-line therapy, they undermined the health of all patients. These patients and their doctors deserved to know the truth about fluoroquinolones. Now, that truth is finally being let out of the bag.